12:00 AM
Jan 26, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ecabet sodium: Phase IIb data

Data from a double-blind, placebo-controlled, U.S. Phase IIb trial in 144 patients showed non-significant changes on 2 of 4 co-primary endpoints, although the company said the study was not powered for statistical significance. Ecabet showed a "strong positive" trend in the objective sign of TFBUT, a "positive" trend in...

Read the full 221 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >